Status:
UNKNOWN
Clinical Outcomes With a New Monofocal IOL Enhanced for Intermediate Vision
Lead Sponsor:
Dar Al Shifa Hospital
Conditions:
Presbyopia
Eligibility:
All Genders
40+ years
Phase:
NA
Brief Summary
phacoemulsification with insertion of EYHANCE IOL to improve near and intermediate vision
Detailed Description
insertion of new intraocular lens enhanced for intermediate vision
Eligibility Criteria
Inclusion
- normal ocular examination apart from cataract.
Exclusion
- previous ocular surgery.
- ocular pathology or corneal abnormalities.
- endothelial cell count below 2000 cells/mm2.
- corneal astigmatism greater than 1.0 diopter (D) measured with Scheimpflug tomography (Sirius, CSO, Italy).
Key Trial Info
Start Date :
November 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 30 2021
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT04904887
Start Date
November 1 2020
End Date
October 30 2021
Last Update
May 27 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Daralshifa hospital
Kuwait City, Kuwait